FCGR2A and autoimmune disease: The promising trivalent Fc oligomer CSL730/Fc3Y with avid binding properties to FcγRs but without FcγR activation potential has proven to broadly dampen FcγR-mediated cellular activation without activating immune cells and showed therapeutical efficacy in preclinical animal models of Ab-mediated autoimmune diseases [81].